Terlipressin

Terlipressin is a vasopressin analogue with potent vasoactive properties. Terlipressin is a highly selective vasopressin V1 receptor agonist that reduces the splanchnic blood flow and portal pressure and controls acute variceal bleeding. Terlipressin exerts anti-inflammatory and anti-oxidative effects. Terlipressin has the potential for hepatorenal syndrome and norepinephrine-resistant septic shock research[1][2][3][4][5].

Product Specifications

CAS Number

[14636-12-5]

UNSPSC

12352005

Hazard Statement

H302-H312-H332

Target

Vasopressin Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Endocrinology; Inflammation/Immunology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Terlipressin.html

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C([C@H](CSSC[C@@H](C(N[C@H](C1=O)CC2=CC=C(O)C=C2)=O)NC(CNC(CNC(CN)=O)=O)=O)NC([C@@H](NC([C@@H](NC([C@](N1)([H])CC3=CC=CC=C3)=O)CCC(N)=O)=O)CC(N)=O)=O)N(CCC4)[C@@H]4C(N[C@@H](CCCCN)C(NCC(N)=O)=O)=O

Molecular Formula

C52H74N16O15S2

Molecular Weight

1227.37

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P363-P501

References & Citations

[1]Zi-Meng Liu, et al. Terlipressin Protects Intestinal Epithelial Cells Against Oxygen-Glucose Deprivation/Re-Oxygenation Injury via the Phosphatidylinositol 3-kinase Pathway. Exp Ther Med. 2017 Jul;14 (1) :260-266.|[2]Yeun Tarl Fresner Ng Jao, et al. Refractory Torsade De Pointes Induced by Terlipressin (Glypressin) . Int J Cardiol. 2016 Nov 1;222:135-140.|[3]Xiqiang Liu, et al. Signaling Through Hepatocyte Vasopressin Receptor 1 Protects Mouse Liver From Ischemia-Reperfusion Injury. Oncotarget. 2016 Oct 25;7 (43) :69276-69290.|[4]Xinmiao Zhou, et al. Terlipressin for the Treatment of Acute Variceal Bleeding: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Medicine (Baltimore) . 2018 Nov;97 (48) :e13437.|[5]Alastair O'Brien, et al. Terlipressin for Norepinephrine-Resistant Septic Shock. Lancet. 2002 Apr 6;359 (9313) :1209-10.